Massachusetts Institute of Technology

Cj Cheiljedang Corporation

Allan Stuart Myerson

David Brancazio

Mohammad A Azad

Gregory J Hammersmith

Bernhardt Levy Trout

Shin Yee Wong

Torsten Stelzer

Klavs F Jensen

Jie Chen

Trevor Alan Hatton

Ping Zhang

Timothy F Jamison

Andrea Adamo

David R Snead

Jean-Christophe Monbaliu

Mohsen Behnam

Nopphon Weeranoppanant

Clemence Neurohr

Gerard Capellades Mendez

Kersten Rapp

Naomi Elizabeth Barbara Briggs

Eve Marie Revalor

Juan Guillermo Osorio Caicedo

Won Sik Kim

Patrick Seamus Doyle

Jun-Woo Kim

In Sung Lee

Gregory C Rutledge

Yi Du

Jung-Hoon Chun

Samir Kulkarni

Nikhil Padhye

Salvatore Mascia

Wang Soo Kim

Kee Kahb Koo

Emily Chang

Himanshu Hemant Dhamankar

Keith M Forward

James M B Evans

Ryan Richard Slaughter

Mao Wang

Blair Kathryn Brettmann

Ying Diao

Matthew E Helgeson

Marcus O'Mahony

Yuqing Cui

Keith Chadwick

Jean-Christophe M Monbaliu

Marcus O'mahony

James Mb Evans

Devices and methods for filtering, drying, and mechanically processing active pharmaceutical ingredients are generally described.

Devices and methods for the integrated filtration, drying, and mechanical processing of active pharmaceutical ingredients

Systems and methods for synthesizing chemical products, including active pharmaceutical ingredients, are provided. Certain of the systems and methods described herein are capable of manufacturing multiple chemical products without the need to fluidically connect or disconnect unit operations when switching from one making chemical product to making another chemical product.

Systems and methods for synthesizing chemical products, including active pharmaceutical ingredients

Systems and methods for fabricating ingestible pharmaceutical tablets are provided. Certain of the systems and methods described herein are capable of manufacturing tablets of different dosages without the need to fluidically connect or disconnect unit operations when switching from a tablet having a first dosage to a tablet having a second, different dosage. Certain of the systems and methods described herein are capable of manufacturing compositionally tablets, e.g., tablets with different active pharmaceutical ingredients (APIs).

Systems and methods for the fabrication of tablets, including pharmaceutical tablets

The present application relates to a method for preparing L-methionine crystals with an improved bulk density. As the L-methionine crystals prepared according to the method for preparing L-methionine crystals of the present application may have a bulk density of up to 800 g/L, the L-methionine crystals are expected to reduce storage and transport costs of L-methionine powder and improve working conditions due to improved fluidity of the powder.

Method for preparing L-methionine crystals using crystallization technique

Aspects of the disclosure relate to methods and compositions of altering a solution through the use of readily retrievable agents (e.g., a nanoparticle) having one or more functional groups configured to undergo a solvation interaction with a component of the solution. Compositions, systems, and methods for crystallizing organic and inorganic compounds from solutions using nanoparticles surface coated with functional groups that create a supersaturated state in the solution and reversal thereof. Compositions, systems, and methods for purifying water or active pharmaceutical ingredients. Compositions, systems, and methods for increasing the solubility of a solution and reversal of the same. Compositions, systems, and methods for decreasing the solubility of a crystallized compound and reversal of the same.

Reversible control of solution solubility using functionalized nanoparticles

The present invention generally relates to systems and methods for pressure driven flow crystallization. In some embodiments, the system comprises a comprising a cavity and a mixing mechanism. In some embodiments, one or more inlets facilitate the transfer of one or more reagent streams to the cavity. In some such embodiments, the mixing mechanism mixes the first and second reagent streams such that a continuous crystallization and/or generation of a product (e.g., solid particles) in the fluid.

Pressure driven flow crystallizer

The present invention generally relates to methods and systems relating to the selection of substrates comprising crystalline templates for the controlled crystallization of molecular species. In some embodiments, the methods and systems allow for the controlled crystallization of a molecular species in a selected polymorphic form. In some embodiments, the molecular species is a small organic molecule (e.g., pharmaceutically active agent).

Methods and systems relating to the selection of substrates comprising crystalline templates for the controlled crystallization of molecular species

The invention in some aspects relates to devices and methods for nucleating crystals under controlled conditions. In some aspects of the invention, devices and methods are provided for continuous crystallization.

Devices and methods for crystallization

Layer processing for pharmaceuticals, and related systems, methods, and articles are generally described. In some embodiments, ingestible pharmaceutical products (e.g., tablets) can be formed by processing one or more layers containing a pharmaceutically active composition. For example, at least one layer containing a pharmaceutically active composition can be manipulated (e.g., folded, rolled, stacked, etc.) such that the average thickness of the product formed by the manipulation is at least about two times the average thickness of the portions of the layer(s) used to form the product. In some embodiments, after the layer is manipulated, it can be processed (e.g., cut, coated, etc.) to form a final product such as, for example, a tablet.

Layer processing for pharmaceuticals

The present invention generally relates to compositions, methods, and systems relating to controlled crystallization and/or nucleation of a molecular species. In some embodiments, the crystallization and/or nucleation of the molecular species may be controlled by tuning the surface chemistry and/or the morphology of a crystallization substrate. In some embodiments, the molecular species is a small organic molecule (e.g., pharmaceutically active agent).

Compositions, methods, and systems relating to controlled crystallization and/or nucleation of molecular species

Growing community of inventors

Boston, MA, United States of America

Allan Stuart Myerson